3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
2
Phase 3
1
Phase 1/2
1
Status
Unknown
4
Terminated
3
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Cyclophosphamide
741
Cisplatin
688
Gemcitabine
641
Bevacizumab
616
Carboplatin
605
Paclitaxel
601
Docetaxel
565
Radiotherapy
536
Fluorouracil
405
Oxaliplatin
387
Rituximab
369
Doxorubicin
361
Capecitabine
342
Filgrastim
333
Etoposide
330
Dexamethasone
312
Irinotecan
309
pembrolizumab
282
Leucovorin
274
Cetuximab
268
Cytarabine
242
Erlotinib Hydrochloride
231
Nivolumab
228
Prednisone
227
Trastuzumab
225
Vincristine
221
Bortezomib
221
Methotrexate
207
Pemetrexed
199
fludarabine phosphate
195
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Completed
×
tegafur-gimeracil-oteracil
×
Clear all
NCT01845337
2023-05-12
TOFFEE
University of Edinburgh
Phase 2
Completed
59 enrolled
NCT02128243
2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2
Completed
242 enrolled